Clinical trials: Inflammatory Disorder
Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
CM-101 is developed as treatment for medical conditions involving inflammatory and fibrotic mechanisms such as non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC), Systemic Sclerosis (SSc)
- Trial name
- NCT06037577
- Testing
- CM-101
- Where
- Israel
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- ChemomAb Ltd.
Ulcerative Colitis
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.
- Trial name
- NCT00355901
- Testing
- Visilizumab (Nuvion®; HuM291)
- Where
- 40 sites in United States, Australia and 12 more
- Volunteers
- 300 people
- Sponsor
- PDL BioPharma, Inc.
Inflammatory Bowel Disease, Intestinal Fistula
Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas
The objective of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 in treating patients with mild to moderately severe Crohn's disease who have fistulas.
- Trial name
- NCT00321412
- Testing
- AST-120
- Where
- 88 sites in United States, Austria and 10 more
- Volunteers
- 191 people
- Sponsor
- Ocera Therapeutics
Eyes Dry Chronic, Chronic Conjunctivitis of Both Eyes
CDL Validation Study
Ocular surface photography is significantly limited in standardization and reproducibility. This reduces its applicability for clinical monitoring of acute or chronic disease.
- Conditions
- Eyes Dry Chronic, Chronic Conjunctivitis of Both Eyes, Limbal Stem-cell Deficiency, Eye Lesion
- Trial name
- NCT05461469
- Where
- Austria
- Volunteers
- 104 people
- Sponsor
- Occyo GmbH
Lentigo, Solar Lentigo
Interventional, Monocentric, Double-blind Randomized Category 2b Study Evaluating the Evaluation of the Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post -Inflammatory Hyperpigmentation (Pih)) on the Face
The goal of this clinical trial is to compare the 2 different prototype of cytoselectivecryotherapy devices (name of the devices : CRYONOVE) use in brown spots on the face of subject from different ethnicities.
- Conditions
- Lentigo, Solar Lentigo, Post Inflammatory Hyperpigmentation
- Trial name
- CS5_10 (NCT06361251)
- Testing
- CRYONOVE (EC14_4osc), CRYONOVE (EC05osc)
- Where
- South Africa
- Volunteers
- 30 people
- Sponsor
- Cryonove Pharma
Ulcerative Colitis
Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis
This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of the human anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab (ADA) in patients with…
- Trial name
- NCT00408629
- Testing
- adalimumab
- Where
- 108 sites in United States, Argentina and 16 more
- Volunteers
- 518 people
- Sponsor
- Abbott
Inflammatory Bowel Disease, Colitis, Ulcerative
LMT503 First-in-human SAD, MAD, and FE Study
This is a double-blind, randomized, placebo-controlled study, consisting of a single ascending dose (SAD) part with integrated food effect (FE) arm, and a multiple ascending dose (MAD) part to assess the safety, tolerability, and…
- Conditions
- Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn Disease
- Trial name
- NCT05659953
- Testing
- LMT503
- Where
- Netherlands
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Lmito Therapeutics Inc.
Crohn's Disease
A Study of Abatacept in Patients With Active Crohn's Disease
The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active Crohn's Disease in patients who have not had an adequate response to other therapies.
- Trial name
- NCT00406653
- Testing
- abatacept
- Where
- 101 sites in United States, Australia and 15 more
- Volunteers
- 451 people
- Sponsor
- Bristol-Myers Squibb
Crohn's Disease
A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease
The purpose of this study is to evaluate the safety and effectiveness of the study drug Mirikizumab in participants with active Crohn's Disease.
- Trial name
- SERENITY (NCT02891226)
- Testing
- Mirikizumab
- Where
- 108 sites in United States, Australia and 12 more
- Volunteers
- 191 people
- Sponsor
- Eli Lilly and Company
Inflammatory Acne
Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne
The main purpose of this study is to assess preliminary efficacy and safety of LYS006 in patients with moderate to severe inflammatory acne and to determine if LYS006 has an adequate clinical profile for further clinical…
- Trial name
- NCT03497897
- Testing
- LYS006 20 mg, LYS006 2 mg
- Where
- 17 sites in United States, Czechia and 4 more
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)
The purpose of this study is to evaluate the efficacy and safety of Ontamalimab in inducing clinical remission and endoscopic response in participants with moderate to severe Crohn's Disease.
- Trial name
- CARMEN CD 306 (NCT03566823)
- Testing
- Ontamalimab
- Where
- 145 sites in United States, Argentina and 18 more
- Volunteers
- 34 people
- Sponsor
- Shire
Inflammation and Fibrosis, Diabetes
Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome
This is a Phase 2, single-centre, single-arm, open-label study of the safety, tolerability, and effects on biomarkers of PBI-4050 in subjects with Alström syndrome for a treatment duration of 24 weeks.
- Trial name
- NCT02739217
- Testing
- PBI-4050
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Liminal BioSciences Ltd.
Ulcerative Colitis
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.
- Trial name
- GEMINI I (NCT00783718)
- Testing
- vedolizumab
- Where
- 105 sites in United States, Canada and 1 more
- Volunteers
- 895 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Crohn Disease
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy
The purpose of this study is to evaluate the efficacy, safety, drug levels, and drug effects of ozanimod in pediatric participants with moderately to severely active Crohn's Disease.
- Trial name
- NCT05470985
- Testing
- Ozanimod
- Where
- 46 sites in United States, Australia and 7 more
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
Biomarkers, Acute Kidney Injury
Vancomycin Exposure and Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid
The goal of this observational study is to understand whether a wearable sensor (the Nutromics Sensor Device) can accurately measure drug and biomarker levels in the fluid just under the skin (interstitial fluid), instead of…
- Conditions
- Biomarkers, Acute Kidney Injury, Sepsis
- Trial name
- VENTURE (NCT07893223)
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- Nutromics
Ulcerative Colitis
Effectiveness of Cortiment® in Patients With Ulcerative Colitis
The purpose of this study is to evaluate Cortiment® with regard to its use by clinicians in routine clinical practice and its effectiveness and tolerability in a real-life setting.
- Trial name
- CORE Practice (NCT02586259)
- Testing
- budesonide MMX®
- Where
- 8 sites in Canada, Germany and 6 more
- Volunteers
- 378 people
- Sponsor
- Ferring Pharmaceuticals
Iron Deficiency Anemia Secondary to IBD or Gastric Bypass
Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass
The primary objective of this study is to evaluate the treatment response of Injectafer vs. oral iron to baseline hepcidin levels to determine if any of these select IBD or Gastric Bypass patients may demonstrate to be…
- Trial name
- NCT02086968
- Testing
- Injectafer, Ferrous Sulfate tablets
- Volunteers
- 198 people
- Sponsor
- American Regent, Inc.
Venous Leg Ulcer (VLU)
EVALUATION OF THE EFFICACY AND TOLERANCE OF VASHE SOLUTION VERSUS SALINE SOLUTION IN THE TREATMENT OF VENOUS OR MIXED LEG ULCERS PRESENTING INFLAMMATORY SIGNS SUGGESTING HEAVY BACTERIAL LOAD
Evaluation of the efficacy (reduction of inflammatory signs suggesting a local infection) and tolerance (emergence and nature of adverse event) of Vashe solution vs Saline solution in the treatment of venous or mixed leg ulcers…
- Trial name
- NCT07440797
- Testing
- Saline solution, Vashe solution
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Laboratoires URGO
Inflammatory Bowel Disease
Open-label PK Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg IV Infusion to Patients With Inflammatory Bowel Disease
The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer(R)in patients suffering from inflammatory bowel disease
- Trial name
- NCT01213680
- Testing
- Monofer (iron isomaltoside 1000), Monofer
- Volunteers
- 16 people
- Sponsor
- Pharmacosmos A/S
Skin Inflammation
Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response
This trial will test the feasibility of various imaging devices to detect local skin inflammation prior to clinical manifestation.
- Trial name
- NCT03192280
- Testing
- Leukotriene B4, FLIR One, SCIO
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.